Diagnosis of venous leakage by 133Xe corporeal clearance after intracavernous injection of prostaglandin E1 in poorly responding patients

Yeh, Su‐Ling; Liu, R. S.; Chen, K. K.; Wu, Liang; Ng, Meijne; Chu, Yum Kung; Chen, M. T.; Chang, Shun‐Hsyung

doi:10.1097/00006231-199201000-00005

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 244 patients were treated with single 20-gg doses of PGE1 in 5 studies in which PGE~ was used in conjunction with the ~33Xe washout test [37,38,43,108,118]. In another study in 14 patients with venogenic ED [118] PGE~ significantly enhanced 133Xe corporeal clearance; this finding led these investigators to conclude that ~33Xe corporal clearance after a PGE~ injection is a useful and sensitive technique for detecting venous leakage. In another study in 14 patients with venogenic ED [118] PGE~ significantly enhanced 133Xe corporeal clearance; this finding led these investigators to conclude that ~33Xe corporal clearance after a PGE~ injection is a useful and sensitive technique for detecting venous leakage.…”

Section: Use Of Pge1 Withmentioning

confidence: 99%

Intracavernous prostaglandin E1 in erectile dysfunction

Linet

Neff

1994

Clin Investig

View full text Add to dashboard Cite

Prostaglandin E1 (PGE1) is a naturally occurring substance that is present in a variety of mammalian tissues, including the semen of fertile men. Its use in the diagnosis and treatment of erectile dysfunction has been extensively studied. In doses of 10-20 micrograms, PGE1 produces full erections in 70-80% of patients with erectile dysfunction. In diagnostic use PGE1 is employed as a simple office test and in conjunction with various hemodynamic tests. Self-injection of PGE1, either with the patient or his partner administering the injection, is a minimally invasive and effective treatment for erectile dysfunction in patients with organic or psychogenic erectile dysfunction. Its use is contraindicated in patients with sickle cell anemia, severe coagulopathy, schizophrenia or severe psychiatric disorder, poor manual dexterity, severe venous incompetence, or severe systemic disease. As calculated from data in the published literature, the most frequent side effects are pain at the injection site or during erection (occurring in 16.8% of patients), hematoma/ecchymosis (1.5% of patients), and prolonged erection/priapism (1.3% of patients). The potential for prolonged erection/priapism, the most serious side effect, can be minimized by careful titration of the dose and through patient education. Systemic side effects occur rarely during PGE1 use. During extended use, patients should be monitored for potential long-term side effects, such as fibrosis and angulation.

show abstract